文献速递帕金森病与运动障碍

帕金森病运动进展与黑质纹状体神经变性

Motor Progression and Nigrostriatal Neurodegeneration in Parkinson Disease.
PubMed 文献 · Ann Neurol · 2022-05-02

研究纳入93例帕金森病患者,按运动症状持续时间和有无运动波动分为早期和晚期亚组,用123I-ioflupane SPECT评估纹状体多巴胺能末梢变性、用NM-MRI评估黑质神经元密度,发现早期运动障碍与纹状体摄取下降平行,晚期则与黑质NM-MRI信号负相关。

要点

  • 早期帕金森病患者药物关期运动障碍与纹状体123I-ioflupane摄取下降平行。
  • 早期患者运动障碍与黑质NM-MRI信号降低无相关性。
  • 晚期患者药物关期运动障碍与黑质NM-MRI信号呈显著负相关,与纹状体摄取无关。

核心结论

  • 作者提出纹状体多巴胺能末梢丢失(123I-ioflupane SPECT)和黑质多巴胺神经元丢失(NM-MRI)可分别作为早期和晚期运动损害的生物标志物。

研究设计与样本

  • 研究纳入93例帕金森病患者,按运动症状持续时间和有无运动波动分为早期和晚期亚组。

主要发现

  • 早期帕金森病患者(运动症状≤8或10年)药物关期运动功能障碍与纹状体123I-ioflupane摄取下降平行,但与黑质NM-MRI信号降低无相关性。
  • 晚期帕金森病患者(运动症状>8或10年且伴运动波动)药物关期运动缺损程度与纹状体123I-ioflupane摄取无相关性,但与黑质NM-MRI信号呈显著负相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The motor severity in Parkinson disease (PD) is believed to parallel dopaminergic terminal degeneration in the striatum, although the terminal was reported to be virtually absent by 4 years postdiagnosis. Meanwhile, neuromelanin-laden dopamine neuron loss in the substantia nigra (SN) elucidated a variability at early stages and gradual loss with less variability 10 years postdiagnosis. Here, we aimed to clarify the correlation between motor impairments and striatal dopaminergic terminal degeneration and nigral neuromelanin-laden dopamine neuron loss at early to advanced stages of PD. METHODS: Ninety-three PD patients were divided into early and advanced subgroups based on motor symptom duration and whether motor fluctuation was present. Striatal dopaminergic terminal degeneration was evaluated using a presynaptic dopamine transporter tracer, 123 I-ioflupane single photon emission computed tomography (SPECT). Nigral neuromelanin-laden dopamine neuron density was assessed by neuromelanin-sensitive magnetic resonance imaging (NM-MRI). RESULTS: In patients with early stage PD (motor symptoms for ≤8 or 10 years), motor dysfunction during the drug-off state was paralleled by a decline in 123 I-ioflupane uptake in the striatum despite the absence of a correlation with reductions in NM-MRI signals in SN. Meanwhile, in patients with advanced stage PD (motor symptoms for >8 or 10 years and with fluctuation), the degree of motor deficits during the drug-off state was not correlated with 123 I-ioflupane uptake in the striatum, despite its significant negative correlation with NM-MRI signals in SN. INTERPRETATION: We propose striatal dopaminergic terminal loss measured using 123 I-ioflupane SPECT and nigral dopamine neuron loss assessed with NM-MRI as early stage and advanced stage motor impairment biomarkers, respectively. ANN NEUROL 2022;92:110-121.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Furukawa K, Shima A, Kambe D, et al. Motor Progression and Nigrostriatal Neurodegeneration in Parkinson Disease. Ann Neurol. 2022. PMID: 35428994. doi:10.1002/ana.26373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。